CNSX:LOVE Cannara Biotech (LOVE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cannara Biotech Stock (CNSX:LOVE) Get Cannara Biotech alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume69,070 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$3.13Consensus RatingBuy Company Overview Cannara Biotech Inc. is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec's low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands. Read More Receive LOVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cannara Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LOVE Stock News HeadlinesCannara Completes Acquisition of Medican Organic Inc.May 7 at 8:06 AM | finance.yahoo.comCannara Biotech Inc (LOVFF) Q2 2026 Earnings Call Highlights: Revenue Growth and Market ...April 16, 2026 | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 9 at 1:00 AM | Paradigm Press (Ad)Cannara Biotech Shares Slide as Revenue Growth Misses ViewsApril 14, 2026 | marketwatch.comCannara Biotech Inc.: Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in QuébecApril 14, 2026 | finanznachrichten.deCannara Biotech Posts Solid Q2, Becomes Top Cannabis Retailer in QuébecApril 14, 2026 | tipranks.comStocks in play: Cannara Biotech Inc.April 7, 2026 | ca.finance.yahoo.comCannara Biotech Sets Date for Q2 2026 Results as Haywood Securities Initiates CoverageApril 7, 2026 | tipranks.comSee More Headlines LOVE Stock Analysis - Frequently Asked Questions How do I buy shares of Cannara Biotech? Shares of LOVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cannara Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cannara Biotech investors own include Aurora Cannabis (ACB), FSD Pharma (HUGE), Organigram Global (OGI), Aurora Cannabis (ACB), Netflix (NFLX), Qualcomm (QCOM) and Roku (ROKU). Industry, Sector and Symbol Stock ExchangeCNSX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCNSX:LOVE CIKN/A Webcannara.ca PhoneN/AFaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Cannara Biotech$3.13 High Price Target$3.25 Low Price Target$3.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (CNSX:LOVE) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cannara Biotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Cannara Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.